Methotrexate Injection Recalled Due to Presence of Particulate Matter
Mylan Institutional LLC is recalling Methotrexate Injection vials due to the presence of particulate matter.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 5/5 (Critical).
Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The agency classification is FDA Class I, which is defined as a situation where use of or exposure to a violative product may cause serious adverse health consequences or death. Per the rubric, FDA Class I recalls are assigned a score of 5.
Plain-English summary
Mylan Institutional LLC is recalling Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vials. The recall is being conducted because of the presence of particulate matter in the product.
The affected product is distributed by Pfizer Labs, Division of Pfizer Inc., and manufactured for Mylan Institutional LLC. The recall covers specific lots: Lot 7801082 (Exp. 07/15) and Lot 7801421 (Exp. 09/16). The distribution pattern is nationwide and Puerto Rico.
Healthcare providers and patients should check their inventory for the specific lot numbers and expiration dates listed above. If the product is found, it should be quarantined and not administered. Patients who have received the affected product should contact their healthcare provider for guidance.
The recalled product
- Product
- Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC…
- Manufacturer
- Mylan Institutional LLC
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: a) 7801082
- Exp. 07/15 and b) 7801421
- Exp. 09/16
Distribution
Related recalls
Same manufacturer · Mylan Institutional LLC
See all →- LowThiamine HCl Injection Recall: Vials with Incorrect Lot Numbers
FDA (Drugs) · 2021-06-09
- CriticalMylan Recalls Amiodarone Hydrochloride Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- CriticalMylan Recalls Tranexamic Acid Injection Due to Labeling Mix-Up
FDA (Drugs) · 2020-09-09
- SevereMylan Recalls Daptomycin Injection Due to Particulate Matter
FDA (Drugs) · 2020-08-12
- ModerateMylan Recalls Aloprim Injection Vials Due to Discoloration
FDA (Drugs) · 2020-05-27
Same hazard · particulate matter
See all →- ModerateIMAAVY Injection Recalled for Presence of Particulate Matter
FDA (Drugs) · 2026-10-14
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls Plum Administration Sets Due to Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
Similar recalls
- SevereMylan Recalls Gemcitabine Injection Vials Due to Particulate Matter
FDA (Drugs) · 2015-08-26
- SevereMylan Recalls Cytarabine Injection Vials Due to Particulate Matter
FDA (Drugs) · 2015-08-19
- SevereMylan Recalls Gemcitabine for Injection Due to Particulate Matter
FDA (Drugs) · 2015-08-26
- SevereHospira Recalls Methotrexate Injection Due to Embedded Glass Particles
FDA (Drugs) · 2012-09-26
- SevereHospira Recalls Metoclopramide Injection Due to Glass Particulate Matter
FDA (Drugs) · 2013-11-27
- SevereLidocaine injection recalled due to glass particulate matter
FDA (Drugs) · 2023-11-15